Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

PHASE4CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

May 12, 2016

Primary Completion Date

November 14, 2016

Study Completion Date

November 14, 2016

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

fingolimod

Trial Locations (26)

10713

Novartis Investigative Site, Berlin

12163

Novartis Investigative Site, Berlin

13347

Novartis Investigative Site, Berlin

24105

Novartis Investigative Site, Kiel

24161

Novartis Investigative Site, Altenholz-Stift

29223

Novartis Investigative Site, Celle

37073

Novartis Investigative Site, Göttingen

41239

Novartis Investigative Site, Mönchengladbach

44137

Novartis Investigative Site, Dortmund

51375

Novartis Investigative Site, Leverkusen

53844

Novartis Investigative Site, Troisdorf

57076

Novartis Investigative Site, Siegen

60313

Novartis Investigative Site, Frankfurt

63739

Novartis Investigative Site, Aschaffenburg

64711

Novartis Investigative Site, Erbach im Odenwald

71032

Novartis Investigative Site, Böblingen

73760

Novartis Investigative Site, Ostfildern

76889

Novartis Investigative Site, Klingenmünster

78224

Novartis Investigative Site, Singen

81829

Novartis Investigative Site, München

82008

Novartis Investigative Site, Unterhaching

86633

Novartis Investigative Site, Neuburg an der Donau

89073

Novartis Investigative Site, Ulm

93138

Novartis Investigative Site, Lappersdorf

01307

Novartis Investigative Site, Dresden

07740

Novartis Investigative Site, Jena

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY